Metastatic Neuroendocrine Prostate Cancer

Oncology

20 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
[177Lu]Lu-DOTA-TATE	Novartis AG (NVS)
[68ga]ga-psma-11	Novartis AG (NVS)
gonadotropin-releasing hormone analogues	NOVARTIS AG (NVSEF)

Phase 2(1)

Drug	Company
[177Lu]Lu-DOTATATE	Novartis AG (NVS)

Phase 1(9)

Drug	Company
[177lu]lu-psma-617	Novartis AG (NVS)
[177Lu]Lu-PSMA-617	Novartis AG (NVS)
[68ga]ga-psma-11	Novartis AG (NVS)
177lu-dfc413	Novartis AG (NVS)
antiemetics & antinauseants	Novartis AG (NVS)
antiemetics & antinauseants	NOVARTIS AG (NVSEF)
gnrh antagonists	NOVARTIS AG (NVSEF)
gnrh antagonists	Novartis AG (NVS)
gonadotropin-releasing hormone analogues	Novartis AG (NVS)

Phase 1/Phase 2(6)

Phase 4(1)

Drug	Company
[177lu]lu-neob	Novartis AG (NVS)

BioSniper tracks 20 drugs in development for Metastatic Neuroendocrine Prostate Cancer across 2 companies.

There are 1 clinical trial targeting Metastatic Neuroendocrine Prostate Cancer tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.